BioNTech SE (BNTX) Accounts Payables (2018 - 2025)

BioNTech SE has disclosed Accounts Payables across 8 years of filings, most recently posting $622.6 million for Q4 2025.

• Accounts Payables for Q4 2025 came in at $622.6 million, up 36.55% year-over-year; the trailing twelve-month figure through Dec 2025 was $622.6 million (up 36.55% YoY), and the FY2025 annual result was $604.3 million, up 32.54% from the prior year.
• Accounts Payables came in at $622.6 million for Q4 2025 at BioNTech SE, up from $467.4 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $949.3 million in Q2 2024 to a low of $32.1 million in Q1 2023.
• The 5-year median for Accounts Payables is $317.6 million (2024), against an average of $381.5 million.
• Across the five-year window, Accounts Payables tumbled 76.88% in 2023 and surged 911.45% in 2024, its largest moves.
• BioNTech SE's Accounts Payables stood at $183.0 million in 2021, then advanced by 13.77% to $208.2 million in 2022, then surged by 82.91% to $380.9 million in 2023, then gained by 19.71% to $456.0 million in 2024, then jumped by 36.55% to $622.6 million in 2025.
• The last three Accounts Payables figures came in at $622.6 million (Q4 2025), $467.4 million (Q3 2025), and $570.7 million (Q2 2025), per Business Quant data.